Table 1.

Composition, physico-chemical characteristics and antitumor application of vegetal protein-based nanoparticles.

Protein	Encapsulated Drug	Method of Fabrication	Mean Sizes (nm)	PDI	Z-Potential (mV)	Type of Treated Cancer Cells/Application	Reference
Zein	Daidzin	Modified Antisolvent Precipitation	150–200	0.2–0.3	20	/	[94]
	6,7-dyhydroxicoumarin	pH controlled nanoprecipitation	300–400	0.36	−11 ± 18	/	[98]
	Doxorubicin	Phase Separation	200–250	0.15–0.20	~−50	HeLa cells	[106]
	5-Fluorouracil	Phase Separation	100–150	/	−46 ± 1	Liver targeting	[108]
	Paclitaxel	Nanoprecipitation	<200	0.2	~−30	MCF-7; K562	[113]
	Curcumin	Antisolvent precipitation	109	0.12	~−30	Caco-2	[117]
	Exemestane and Resveratrol	Interfacial deposition	127 ± 3	0.13	~−32	Breast Cancer	[125]
	Vorinostat and Bortezomib	Phase Separation	150	0.20	−20/−30	Metastatic prostate cancer	[126]
Gliadin	All-Trans Retinoic Acid	Desolvation	~500	/	−4	/	[130]
	Paclitaxel	Desolvation and Film Hydration	160 ± 20	0.18	−21 ± 3	MCF-7; MDA-MB-231	[138]
	Cyclophosphamide	Electrospray deposition	~220	/	~18	Breast cancer cells	[142]
	Curcumin	Desolvation	~200	0.4	~−20	Colon cancer	[143]
Legumin	Methylene Blue	pH coacervation	250–300	/	~−40	/	[148]
Soy	Curcumin	Desolvation	220–286	/	~−35	/	[154]
Soy-Folate	Curcumin	Desolvation	170–300	/	−36	Caco 2	[157]
Soy-folate	Doxorubicin	Desolvation	232	/	−28, pH 5; −41, pH 10	293 T, MCF-7, SH-SY5Y cells	[158]
Soy	Doxorubicin	Desolvation	206	/	−20, pH 5; −30, pH 10	293 T, MCF-7, SH-SY5Y	[158]
Soy	Docetaxel	Antisolvent precipitation-ultrasonication	~250	0.3–0.4	~−10/−15	/	[159]